CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Leyden Labs is developing a nasal spray platform using a broadly neutralizing anti-influenza antibody to combat respiratory infectious diseases. This innovative approach aims to enhance pandemic preparedness by providing targeted protection against evolving viral threats, focusing on EU healthcare providers for initial…
Respiratory infectious diseases pose a significant threat to global health, spreading rapidly and hindering containment.
The COVID-19 pandemic, with over 450 million cases in two years, highlighted the need for effective preventive measures beyond vaccines and antivirals, which have notable limitations.Leyden Labs is pioneering a groundbreaking platform to counter evolving viral threats with nasal sprays developed using the world's most broadly neutralizing anti-influenza antibody (name disclose…
LEYDEN LABORATORIES BV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
